Skip to main content
Andrew Leavitt, MD, Hematology, San Francisco, CA

AndrewD.LeavittMD

Hematology • San Francisco, CA

Blood Banking & Transfusion Medicine, Clotting Disorder, Hemophilia & Bleeding Disorder

Professor, Laboratory Medicine, UCSF School of Medicine

Join to view full profile

Dr. Leavitt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Leavitt's full profile

Already have an account?

  • Office

    505 Parnassus Ave
    San Francisco, CA 94143
    Phone+1 415-514-3432
    Fax+1 415-514-3433

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1988 - 1989
  • University of Michigan
    University of MichiganResidency, Internal Medicine, 1986 - 1988
  • University of Michigan
    University of MichiganInternship, Internal Medicine, 1984 - 1985
  • Harvard Medical School
    Harvard Medical SchoolClass of 1984

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1989 - 2025
  • MI State Medical License
    MI State Medical License 1987 - 1991
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com

Publications & Presentations

PubMed

Abstracts/Posters

  • Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial
    Andrew D. Leavitt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patien...
    Andrew D. Leavitt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms
    Andrew D. Leavitt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Phlebitis after Parenteral Iron Sucrose Administration in Postpartum Women 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Pfizer’s Gene Therapy for Rare Genetic Bleeding Disorder Succeeds in Late-Stage Trial
    Pfizer’s Gene Therapy for Rare Genetic Bleeding Disorder Succeeds in Late-Stage TrialJuly 24th, 2024
  • UCSF Treats Man Who Developed Rare Blood Clot After Johnson and Johnson Vaccine
    UCSF Treats Man Who Developed Rare Blood Clot After Johnson and Johnson VaccineApril 30th, 2021
  • Bay Area Patient Is First MAN to Get Blood Clot After J&J Vaccination
    Bay Area Patient Is First MAN to Get Blood Clot After J&J VaccinationApril 26th, 2021
  • Join now to see all

Grant Support

  • Molecular Mechanisms Of TPO Induced MPL Signaling In MegakaryocytesNational Heart, Lung, And Blood Institute2001–2005
  • Novel Systems For The Study Of MegakaryocytopoiesisNational Heart, Lung, And Blood Institute1996–2000

Dr. Andrew Leavitt, Dr. Andrew Leavitt, MD, Dr. A Leavitt, Dr. Andrew D. Leavitt